Benefit to patients and the NHS of cardiac magnetic resonance imaging (CMR) after Primary percutaneous coronary Intervention (PPCI) Pathway Activation

Sponsor: University of Bristol 

REC Number: 12/SW/0326

Status: Closed

Cardiac magnetic resonance imaging (CMR) can be used to provide detailed pictures of the heart and is used by cardiologists to assess heart function and guide treatment in people who had, or were suspected of having, a heart attack.  We want to set up a multicentre registry by making use of data collected by NHS hospitals in the course of providing usual care for those patients.  Such a registry will provide information on CMR use and how CMR influences patient management. 

The PIPA study is determining whether it is feasible to set up such a registry, for example, whether hospitals can retrieve the data we need and whether we can merge data from different sources (for example, data from the Emergency Department and ward, data describing blood and imaging test results) for a particular patient.  We have finished recruiting patients with suspected heart attacks from four hospitals in the UK (Bristol, Leeds Cardiff and Swansea), two with and two without CMR readily available.  We are assembling a database containing information on patient characteristics, details of interventions and clinical outcomes, and whether CMR has been used or not.  We are requesting hospital activity data from NHS Digital on all patients who participated in the study so that we can add information about future hospital care to the database. We are also requesting data from the Office of National Statistics (ONS) where all births and deaths are recorded. Please contact the study team if you do not wish us to include information about you from NHS Digital or ONS on the database. 


The PIPA health economics paper:

Patient Results Summary

PIPA consensus paper:

PIPA feasibility results paper:

Feasibility of identifying the patient cohort from routinely collected data:

PIPA final report:


Contact Information

Chief Investigator: Prof Barney Reeves


Progenitor cell response after Myocardial Infarction Study

Sponsor: University Hospitals Bristol

REC Number: 09/H0104/58

After a heart attack, stem cells produced in bone marrow are released in large amounts into the blood and travel to the heart to promote the growth of new blood vessels and repair the damage caused by the heart attack.  In people with diabetes this process may be impaired, resulting in less efficient repair and poorer clinical outcomes after a heart attack.

The Promis study is studying patients with and without diabetes who have had a heart attack.  We are collecting blood samples after the heart attack to determine how many stem cells are released in the blood and how these stem cells behave.

Patients also have cardiac magnetic resonance imaging (CMR) scans to investigate the extent of damage to the heart after the heart attack.  We will determine whether the number of stem cells released from bone marrow is influenced by the degree of damage to the heart, and whether the relationship between the number of stem cells released and the amount of damage is lost in patients with diabetes.  


Contact Information

Chief Investigator: Dr Andreas Baumbach


Determination of the SK channel composition contributing to atrial action potential duration and of predictors of response to treatments in patients with or without atrial fibrillation

Funder: NIHR and British Heart Foundation 

Sponsor: University of Bristol 

Status: Published

For the heart to pump blood round the body effectively, the upper and lower heart chambers (atria and ventricles) must beat in a repeated orderly sequence giving rise to what is known as ‘heart rhythm’. Disruptions to normal heart rhythm (‘arrhythmias’) impair blood circulation and can reduce life expectancy. Atrial fibrillation (AF) is the most common arrhythmia and is estimated to effect over 1 million people in the United Kingdom. The SKArF Study aimed to understand how this arrhythmia occurs, with a view to developing more effective treatments.

In the SKArF Study we recruited adult patients undergoing cardiac surgery, both with and without bypass, and asked them to donate small pieces of atrial tissue. We recruited patients both with and without AF, and conducted laboratory experiments on these surplus tissue samples. Chiefly, the study aimed to examine the actions of a specific protein which we hypothesised may be an AF specific antiarrhythmic drug target.

Publication: Role of SK channel activation in determining the action potential configuration in freshly isolated human atrial myocytes from the SKArF study. 

The SKArF study is funded by the British Heart Foundation and is an NIHR Portfolio study. The University of Bristol has overall responsibility for the conduct of the study.

If you have taken part in the SKArF study and you are interested in how we use your data, please see our Privacy Statement



Contact Information

Chief Investigator: Prof Raimondo Ascione


A Randomised Controlled Trial Investigating the Pharmacodynamic Effect of Ticagrelor Monotherapy on Platelet Reactivity in Patients with Coronary Artery Disease: The TEMPLATE Study

Sponsor: University Hospitals Bristol 

REc Number: 14/SC/1309

Status: Closed to Recruitment

The TEMPLATE study is a single centre, open-label randomised controlled trial of the investigational medicinal product ticagrelor.  Patients with blocked or seriously narrowed coronary arteries are treated with a procedure called Percutaneous Coronary Intervention (PCI) in which a stent is inserted to open up the blockage in the coronary artery.  Patients are usually prescribed Dual Antiplatelet Therapy (DAPT) with aspirin and clopidogrel (ADP blocker) course following their PCI.  The use of two different anti-platelet agents helps ensure that platelets are completely inhibited and thereby, are less likely to contribute to abnormal clot formation in the coronary stent.

A new anti-platelet drug called ticagrelor is now available and is given with aspirin to some patients after a stent procedure.  Ticagrelor is a more powerful and reliable ADP blocker than clopidogrel, and is replacing clopidogrel in some patient groups.  There is emerging evidence from healthy volunteer studies that ticagrelor used alone may be sufficient to strongly inhibit platelets, without the need for additional aspirin.  The TEMPLATE study aims to find out if ticagrelor alone is as good as taking ticagrelor and aspirin together at inhibiting platelets, in patients who have had a PCI.

The study population is patients at the end of a DAPT course with clopidogrel and aspirin following a PCI, and who are due to revert aspirin monotherapy as part of standard clinical care at 6 to 12 months after PCI.  Patients who take part in the trial will be randomised to receive either aspirin and ticagrelor or ticagrelor alone for a 4 week interval prior to reverting to aspirin alone. Blood samples for detailed analysis of the extent of platelet inhibition will be taken at three time-points, whilst patients are receiving different combinations of anti-platelet therapy. The main analysis will compare the extent of platelet inhibition between the patient groups receiving ticagrelor alone compared to those receiving ticagrelor plus aspirin.

Publication: Platelet inhibition during ticagrelor monotherapy versus ticagrelor plus aspirin in patients with coronary artery disease (TEMPLATE study): study protocol for a randomised controlled trial. You can read this paper online here: or alternatively download the paper here

Contact Information

Chief Investigator: Dr Andrew Mumford